Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,818
  • Shares Outstanding, K 11,617
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,870 K
  • 60-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.62
  • Low Estimate -0.64
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +21.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.77 +5.37%
on 09/09/19
7.30 -16.71%
on 08/21/19
unch (unch)
since 08/16/19
3-Month
5.77 +5.37%
on 09/09/19
8.19 -25.76%
on 07/01/19
+0.03 (+0.50%)
since 06/17/19
52-Week
3.60 +68.89%
on 12/27/18
9.76 -37.70%
on 04/11/19
-1.52 (-20.00%)
since 09/17/18

Most Recent Stories

More News
Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress

-- Recent Data Supports Potential for Bone Preservation with Edasalonexent in DMD --

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of...

CATB : 6.08 (+1.16%)
JNCE : 3.42 (-0.58%)
Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019...

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2019 financial results before the Nasdaq Global Market open on Thursday, August 8,...

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne...

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative...

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress

-- Sustained Slowing of DMD Disease Progression with Edasalonexent Reinforced by Long Term MoveDMD MRI Data --

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals to Present Data from the MoveDMD(R) trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by...

CATB : 6.08 (+1.16%)
Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on...

CATB : 6.08 (+1.16%)
Top Ranked Momentum Stocks to Buy for April 12th

Top Ranked Momentum Stocks to Buy for April 12th

AAON : 51.04 (+0.67%)
CATB : 6.08 (+1.16%)
ACIW : 32.65 (-0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 6.25
1st Resistance Point 6.13
Last Price 6.07
1st Support Level 5.88
2nd Support Level 5.75

See More

52-Week High 9.76
Fibonacci 61.8% 7.41
Fibonacci 50% 6.68
Last Price 6.07
Fibonacci 38.2% 5.95
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar